Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: LeMaitre Vascular develops, manufactures, and markets medical devices and implants for vascular surgery. The company operates in a single segment with principal product lines including anastomotic clips, vascular grafts, stent grafts, and shunts. Operations are headquartered in Burlington, Massachusetts, with international offices in Germany, Italy, and Japan.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2010 | Six Months Ended June 30, 2010 |
|---|---|---|
| Net Sales | $14,158 | $27,973 |
| Gross Profit | $10,656 | $20,974 |
| Gross Margin | 75.3% | 75.0% |
| Operating Income | $2,008 | $3,278 |
| Net Income | $1,511 | $2,532 |
| Diluted EPS | $0.09 | $0.16 |
| Cash and Cash Equivalents | $25,608 (as of June 30, 2010) | N/A |
| Long-Term Debt | $137 | N/A |
| Operating Cash Flow (6 months) | N/A | $3,460 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% for the quarter and 17% for the six-month period compared to the same periods in 2009. Growth was driven by higher average selling prices and increased volume in the Vascular category (shunts, valvulotomes, remote endarterectomy devices).
- Profitability: The company returned to profitability, reporting net income of $1.5 million for the quarter and $2.5 million for the six months, compared to a net loss of $0.96 million for the six months ended June 30, 2009.
- Margin Expansion: Gross margin improved to 75.3% (Q2) and 75.0% (YTD) from 72.2% and 72.5% in the prior year periods, respectively, due to pricing power and manufacturing efficiencies.
- Product Portfolio Changes: Sales were negatively impacted by the divestiture of the OptiLock Implantable Port (sold June 2010) and the discontinuance of the aSpire covered stent (March 2010).
- Foreign Currency: A strengthening U.S. dollar reduced reported net sales by approximately 2% for the quarter and had a neutral to slightly negative impact on the six-month period.
Guidance, Outlook, and Risks
- Outlook: Management anticipates research and development expenses will increase over time due to patient enrollment in the UNITE and ENTRUST clinical trials. The company expects to fund operations and capital requirements from existing cash reserves for at least the next 12 months.
- Capital Allocation: The Board authorized a stock repurchase program up to $5.0 million. As of June 30, 2010, $3.8 million remained available. The company repurchased $0.7 million of stock in the first six months of 2010.
- Debt Facility: The company terminated its $10 million revolving credit facility with Brown Brothers Harriman & Co. effective August 23, 2010. There were no borrowings outstanding under this facility at June 30, 2010.
- Risks: Key risks include dependence on senior management, the impact of foreign currency fluctuations (approx. 40% of sales are foreign-denominated), and the need for regulatory approvals for new products. The company maintains a valuation allowance against substantially all deferred tax assets.
Investor Verification Checklist
- Cash Position: Verify the $25.6 million cash balance and the composition of marketable securities ($0.3 million) to assess liquidity runway.
- Revenue Quality: Confirm the sustainability of the 12-17% revenue growth, noting the offsetting effects of product divestitures and currency headwinds.
- Debt Status: Note the termination of the credit facility in August 2010 and verify the company's ability to secure future financing if needed.
- Tax Position: Review the valuation allowance on deferred tax assets and the utilization of net operating loss carryforwards, which currently reduce the effective tax rate.
- Product Mix: Monitor the performance of the Vascular category versus the declining Endovascular category (specifically TAArget stent graft sales).